Fasting C-Peptide: Clinical Assessment of Endogenous Beta-Cell Reserve

#Overview

C-peptide (connecting peptide) is a 31-amino-acid polypeptide chain produced by the beta-cells of the pancreatic islets of Langerhans during the enzymatic processing of proinsulin into mature insulin. In human physiology, insulin is not synthesized directly as an active hormone. The beta-cell first translates preproinsulin, which is cleaved in the rough endoplasmic reticulum into proinsulin. Within the Golgi apparatus and secretory vesicles, endopeptidases cleave proinsulin to liberate one molecule of biologically active insulin and one molecule of C-peptide in an exact 1:1 equimolar ratio.

Despite this simultaneous release into the portal venous circulation, insulin and C-peptide exhibit fundamentally distinct physiological clearance pathways. While circulating insulin undergoes roughly 50 percent first-pass extraction and degradation by the liver, C-peptide passes through the hepatic circulation entirely unhindered. C-peptide has an elimination half-life of approximately 20 to 30 minutes, compared to just 4 to 6 minutes for insulin, and is cleared primarily by renal catabolism. Consequently, measuring fasting serum C-peptide provides an exceptionally stable, uncompromised biological index of true endogenous pancreatic insulin secretory capacity.

#What It Measures

A fasting C-peptide test quantifies the biological concentration of connecting peptide in venous blood following an overnight fast:

• Endogenous vs. Exogenous Insulin Distinction: Standard synthetic, animal, or analogue insulins (such as glargine, detemir, lispro, or aspart) do not contain C-peptide. Because standard insulin immunoassays often cannot distinguish between injected pharmaceutical insulin and endogenous hormone, or are distorted by anti-insulin antibodies, C-peptide serves as the sole dependable marker of residual pancreatic function in patients receiving insulin therapy.
• Glucodependent Secretory State: C-peptide concentrations must always be interpreted in the direct context of concurrent blood glucose. High ambient glucose levels strongly stimulate beta-cell depolarization and exocytosis. Conversely, profound hypoglycemia normally turns off endogenous insulin and C-peptide secretion.
• Renal Handling Dynamics: Approximately 70 percent of circulating C-peptide is cleared by the kidneys via glomerular filtration followed by tubular reabsorption and intracellular degradation, with less than 5 percent excreted intact into urine. In patients with moderate to severe renal impairment (eGFR < 30 mL/min/1.73m²), C-peptide accumulates in the circulation, causing measured serum concentrations to read higher than actual beta-cell output.

#Specimen & Collection Method

• Sample Type: Venous blood draw (phlebotomy) collected into a serum separator tube (SST, gold top) or plain red-top tube.
• Fasting Requirement: Strict 8- to 10-hour overnight fast. A paired fasting plasma glucose measurement must be drawn simultaneously to contextualize beta-cell output.
• Pre-Analytical Care: The serum must be separated from cellular elements promptly. Hemolysis must be avoided because hemolyzed erythrocytes can interfere with specific automated chemiluminescent platforms.
• Laboratory Methodology: Automated two-site Chemiluminescent Immunoassay (CLIA) or Electrochemoluminescence Immunoassay (ECLIA) standardized against international reference standards (e.g., WHO International Reference Reagent 84/510).

#Key Biomarkers & Reference Ranges

Serum C-peptide reference intervals vary across clinical laboratories depending on the specific analytical assay platform. The ranges below reflect standard adult distributions under true fasting conditions with normal concomitant blood glucose (70 to 99 mg/dL).

#Clinical Indications

Clinicians order a fasting C-peptide test across several crucial diagnostic scenarios:

1. Differentiating Type 1 from Type 2 Diabetes: When the clinical presentation of diabetes is ambiguous, such as in non-obese adults or young patients presenting without classic ketoacidosis, C-peptide determines whether the underlying defect is absolute insulin deficiency or peripheral insulin resistance.
2. Identifying Latent Autoimmune Diabetes in Adults (LADA): Detecting progressive autoimmune destruction in adults initially misclassified with type 2 diabetes who experience rapid oral medication failure.
3. Evaluating Unexplained Hypoglycemia: Investigating documented neuroglycopenic episodes (Whipple's triad). An elevated C-peptide during hypoglycemia confirms endogenous hyperinsulinism (such as an insulinoma or sulfonylurea ingestion), whereas a suppressed C-peptide indicates factitious or accidental exogenous insulin administration.
4. Assessing Beta-Cell Burnout in Longstanding Type 2 Diabetes: Determining whether a patient with advanced type 2 diabetes retains sufficient functional secretory reserve to respond to oral secretagogues or GLP-1 receptor agonists, or requires absolute transition to replacement insulin.
5. Monitoring Pancreatic Islet Cell Transplantation: Assessing graft viability and secretory function following total pancreatectomy or allogeneic islet cell transplantation.

#Testing Frequency Protocol

• Diagnostic Classification Baseline: Performed once at diabetes presentation when diagnostic subtype is uncertain, ideally after glucotoxicity has been resolved (severe hyperglycemia can transiently stun beta-cells).
• LADA Surveillance: Retesting annually or biennially in antibody-positive individuals to track the rate of beta-cell decline and time the initiation of insulin therapy before ketoacidosis develops.
• Post-Surgical Insulinoma Surveillance: Measured periodically following surgical resection of a pancreatic neuroendocrine tumor to verify complete remission or detect recurrence.

#Pre-Test Preparation Protocol

To ensure dependable diagnostic interpretation:

• Fasting Status: Complete an 8- to 10-hour fast overnight. Consume only plain water.
• Hold Exogenous Secretagogues: Patients taking sulfonylureas (such as glimepiride or gliclazide) or meglitinides should consult their physician regarding pausing these medications on the morning of testing, as they directly force beta-cell exocytosis.
• Biotin Interruption: Discontinue high-dose biotin (vitamin B7) supplements for 48 to 72 hours prior to phlebotomy to avoid analytical immunoassay interference.
• Renal Function Verification: Confirm serum creatinine and eGFR, as kidney disease impairs C-peptide clearance and elevates circulating values.

#Interpreting Your Results

Interpreting C-peptide requires aligning the laboratory value with concurrent blood glucose:

#Suppressed or Severely Low C-Peptide (< 0.20 nmol/L or < 0.60 ng/mL)

Indicates severe, absolute endogenous insulin deficiency:

• Type 1 Diabetes Mellitus: Autoimmune destruction of pancreatic beta-cells (mediated by anti-GAD65, IA-2, or ZnT8 antibodies). Values below 0.20 nmol/L confirm near-total loss of insulin secretion and absolute dependency on lifelong exogenous insulin.
• Late-Stage LADA: Progression of adult-onset autoimmune diabetes to complete secretory exhaustion.
• Total Pancreatectomy or Severe Chronic Pancreatitis: Surgical absence or extensive fibrocalcific destruction of pancreatic parenchyma.
• Physiological Suppression During Fasting or Hypoglycemia: In healthy individuals, if blood glucose drops below 55 mg/dL, C-peptide appropriately falls to near-undetectable levels.

#Preserved or Normal C-Peptide (0.20 to 0.66 nmol/L or 0.60 to 2.00 ng/mL)

Indicates substantial remaining endogenous beta-cell function:

• Early LADA or "Honeymoon" Phase of Type 1 Diabetes: Partial beta-cell survival that temporarily reduces exogenous insulin requirements.
• Early Type 2 Diabetes: Beta-cells maintain baseline secretion, but peripheral tissues cannot effectively utilize the released hormone.

#Elevated C-Peptide (> 0.66 nmol/L or > 2.00 ng/mL)

Reflects compensatory hypersecretion or impaired renal clearance:

• Insulin Resistance and Metabolic Syndrome: Pancreatic beta-cells pump out excessive proinsulin and C-peptide to overcome hepatic and skeletal muscle resistance.
• Insulinoma: Autonomous, unregulated hormone secretion from a neuroendocrine tumor of the pancreatic islets, characterized by high C-peptide (> 0.60 nmol/L) in the presence of severe neuroglycopenia (glucose < 55 mg/dL).
• Sulfonylurea or Meglitinide Overdose: Pharmaceutical stimulation of the sulfonylurea receptor (SUR1) driving continuous potassium channel closure and C-peptide secretion.
• Chronic Kidney Disease (CKD): Reduced glomerular filtration leads to biological retention of C-peptide in the bloodstream.

#Diagnostic Correlation Matrix

#Evidence-Based Interventions

When C-peptide results clarify a patient's underlying pancreatic reserve, clinical management can be tailored to the exact physiological defect:

• Insulin Replacement for Absolute Deficiency: Patients with confirmed C-peptide < 0.20 nmol/L require physiological basal-bolus insulin or automated insulin delivery (insulin pump) systems. In these individuals, oral secretagogues (sulfonylureas) are ineffective and can hasten beta-cell exhaustion.
• Preserving Residual Beta-Cell Mass in LADA: In early autoimmune diabetes with borderline C-peptide (0.20 to 0.50 nmol/L), early introduction of low-dose basal insulin reduces metabolic stress on remaining islets, prolonging the preservation of endogenous function.
• Overcoming Resistance in High C-Peptide States: Patients with elevated C-peptide and hyperglycemia harbor adequate secretory capacity but severe tissue resistance. First-line clinical strategies prioritize insulin-sensitizing interventions:
  • Progressive resistance training to stimulate non-insulin contraction-mediated GLUT4 glucose uptake.
  • Dietary carbohydrate refinement and calorie management to lessen secretory demand.
  • Pharmacological agents that do not exhaust beta-cells, such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.

#Key Takeaways